AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CervoMed: HC Wainwright Reiterates Neutral Rating with $11 PT
ByAinvest
Monday, Sep 8, 2025 7:02 am ET1min read
CervoMed: HC Wainwright Reiterates Neutral Rating with $11 PT
CervoMed Inc. (CRVO), a clinical-stage biotechnology company focused on developing treatments for age-related neurological disorders, has received a neutral rating from H.C. Wainwright & Co. with a price target of $11.00 per share. This rating was announced on September 2, 2025 [1].The analyst's report highlighted CervoMed's progress in its Phase 2b RewinD-LB trial for neflamapimod, a p38MAPK inhibitor targeting synaptic dysfunction in dementia with Lewy bodies (DLB). The trial demonstrated a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's disease co-pathology. Additionally, the company reported a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP) at week 32, indicating potential efficacy in slowing neurodegeneration [2].
CervoMed also announced its participation in several upcoming investor conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and Morgan Stanley's 23rd Annual Global Healthcare Conference, both scheduled for September 2025. The company plans to present its latest clinical data and discuss its pipeline of neurological treatments with investors [3].
The company's financial results for the second quarter of 2025 showed grant revenue of $1.8 million, R&D expenses of $5.1 million, and a net loss of $6.3 million. CervoMed reported $33.5 million in cash and equivalents as of June 30, 2025, with funding runway into Q3 2026 [4].
CervoMed's stock price as of September 2, 2025, was $10.095, and its market capitalization was not explicitly stated in the provided materials. However, the company's financial performance and clinical trial results suggest continued investment potential for stakeholders focused on innovative neurological treatments.
References:
[1] https://www.stocktitan.net/news/CRVO/
[2] https://www.stocktitan.net/news/CRVO/
[3] https://www.stocktitan.net/news/CRVO/
[4] https://www.stocktitan.net/news/CRVO/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet